Key results of LUME Lung 1 trial of Nintedanib

Dr. Martin Reck, Head of Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany, and principal investigator of the LUME-Lung 1 trial.

LUME-Lung 1 is a randomised, Phase III trial comparing nintedanib plus docetaxel with placebo plus docetaxel, in patients with advanced non-small cell lung cancer, after first-line chemotherapy has failed.

Listen to Dr. Reck to hear more about the trial results.